The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.

Manish R.  Patel

Honoraria - Bayer; Genentech; Janssen Oncology; Pfizer; Pharmacyclics

Consulting or Advisory Role - Pfizer/EMD Serono; Pharmacyclics/Janssen

Speakers' Bureau - Celgene; Exelixis; Genentech/Roche; Taiho Pharmaceutical

Research Funding - Acerta Pharma (Inst); ADC Therapeutics (Inst); Agenus (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); CicloMed (Inst); Clovis Oncology (Inst); Curis (Inst); cyteir (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Ignyta (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Klus Pharma (Inst); Kyocera (Inst); Lilly (Inst); Loxo (Inst); LSK BioPharma (Inst); Lycera (Inst); Macrogenics (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Phoenix Molecular Designs (Inst); Placon (Inst); Portola Pharmaceuticals (Inst); Prelude Therapeutics (Inst); PubGene (Inst); QiLu Pharmaceutical (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Stemline Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); TopAlliance BioSciences Inc (Inst); Vedanta Biosciences (Inst); Verastem (Inst); Vigeo Therapeutics (Inst); Xencor (Inst)

Todd Michael  Bauer

Employment - Tennessee Oncology

Consulting or Advisory Role - Bayer; Blueprint Medicines; Exelixis; Foundation Medicine; Guardant Health; Ignyta (Inst); Loxo; Moderna Therapeutics (Inst); Pfizer; Pfizer (Inst)

Speakers' Bureau - Bayer

Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Peleton (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Principa Biopharma (Inst); Roche (Inst); Sanofi (Inst); Stemline Therapeutics (Inst); Takeda (Inst); Top Alliance BioScience (Inst)

Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Pfizer; Pharmacyclics; Sysmex

Antonio  Jimeno

Stock and Other Ownership Interests  - Champions Oncology; Suvica

Research Funding - Acerta Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Celldex (Inst); Genocea Biosciences (Inst); HolyStone Therapeutics (Inst); Iovance Biotherapeutics (Inst); Karyopharm Therapeutics (Inst); Kinex (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); OncoMed (Inst); Pfizer (Inst); Roche (Inst)

Patents, Royalties, Other Intellectual Property - Suvica

Ding  Wang

Consulting or Advisory Role - Qurgen; Qurgen

Travel, Accommodations, Expenses - Qurgen

Patricia  LoRusso

Honoraria - Five Prime Therapeutics

Consulting or Advisory Role - Abbvie; Agenus; Agios; Astellas Pharma; AstraZeneca; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-MAB; Immunome; IQvia; Macrogenics; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; Sotio; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME

Research Funding - Genentech (Inst)

Travel, Accommodations, Expenses - Genentech

Khanh Tu  Do

Consulting or Advisory Role - Jackson Laboratory for Genomic Medicine; QED Therapeutics; Seagen

Research Funding - Lilly (Inst)

Salomon M.  Stemmer

Stock and Other Ownership Interests  - canfite; CTG Pharma; DocBoxMD; tyrnovo; VYPE

Consulting or Advisory Role - Novartis

Research Funding - AstraZeneca (Inst); BiolineRx (Inst); Bristol-Myers Squibb (Inst); Can-Fite BioPharma (Inst); Clovis Oncology (Inst); CTG Pharma (Inst); Exelixis (Inst); Geicam (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Moderna Therapeutics (Inst); MSD (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst); Silenseed (Inst); SynCoreBio (Inst); Teva (Inst); Tiziana Life Sciences (Inst)

Travel, Accommodations, Expenses - Genomic Health

Corinne  Maurice-Dror

Research Funding - Moderna Therapeutics (Inst)

Ravit  Geva

Leadership - Pyxis

Honoraria - Bristol-Myers Squibb; Janssen; Medison; MSD; Novartis; Pfizer; Roche; Takeda

Consulting or Advisory Role - Bayer; BOL Pharma; MSD; Novartis

Patents, Royalties, Other Intellectual Property - Options, BOL Pharma

Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Medison; Merck Serono

Sima  Zacharek

Employment - Moderna Therapeutics

Stock and Other Ownership Interests  - Moderna Therapeutics

Andressa S  Laino

Employment - Moderna Therapeutics

Stock and Other Ownership Interests  - Moderna Therapeutics

Jing  Sun

Employment - Moderna Therapeutics

Stock and Other Ownership Interests  - Moderna Therapeutics

Joshua  Frederick

Employment - Moderna Therapeutics

Stock and Other Ownership Interests  - Moderna Therapeutics

Patents, Royalties, Other Intellectual Property - Moderna Therapeutics

Honghong  Zhou

Employment - Moderna Therapeutics

Stock and Other Ownership Interests  - Merck; Moderna Therapeutics

William  Randolph

Employment - Moderna Therapeutics

Stock and Other Ownership Interests  - Moderna Therapeutics; Novartis

Pamela Sarah  Cohen

Employment - Moderna Therapeutics

Stock and Other Ownership Interests  - Moderna Therapeutics

Robert S.  Meehan

Employment - Moderna Therapeutics

Stock and Other Ownership Interests  - Moderna Therapeutics

Ryan J.  Sullivan

Consulting or Advisory Role - ACI Clinical; Array BioPharma; Asana Biosciences; Merck; Novartis; Replimune; Syndax; WorldCare Clinical, LLC

Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Viralytics (Inst)

Other Relationship - Boehringer Ingelheim